Skip to main content
Fig. 2 | Journal of Ophthalmic Inflammation and Infection

Fig. 2

From: Rituximab in refractory Vogt–Koyanagi–Harada disease

Fig. 2

Optical coherence tomography cross-sectional horizontal images of right and left eye (RE and LE, respectively); a (2 days follow-up) showed response to high-dose corticosteroids in both eyes with decrease of neuroretinal detachment that is more evident after 2 weeks of follow-up in b. c (3 months follow-up) revealed first recurrence of macular detachment in left eye first and later in right eye (d, 4 months follow-up) treated with a new high-dose oral corticosteroid therapy associated with bilateral intravitreal injection of ranibizumab and dexamethasone and adalimumab every 15 days. f (5 months follow-up) showed reappearance of retinal detachment, so we added treatment with cyclosporine (100 mg per day) and methotrexate (17.5 mg weekly). g (7 months follow-up) revealed macular detachment, and examination showed recurrence of anterior and posterior inflammation with tinnitus and headache; thus, we started a first infusion of 1 g of rituximab (15 months after onset of symptoms)

Back to article page